Spasticity - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 74 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Spasticity - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Spasticity - Pipeline Review, H2 2014', provides an overview of the Spasticity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spasticity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Spasticity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Spasticity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Spasticity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Spasticity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Spasticity Overview 7
Therapeutics Development 8
Pipeline Products for Spasticity - Overview 8
Pipeline Products for Spasticity - Comparative Analysis 9
Spasticity - Therapeutics under Development by Companies 10
Spasticity - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Spasticity - Products under Development by Companies 15
Spasticity - Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Canbex Therapeutics Ltd. 17
Concert Pharmaceuticals, Inc. 18
Echo Pharmaceuticals B.V. 19
Escape Therapeutics, Inc. 20
GW Pharmaceuticals plc 21
Merz Pharma GmbH & Co. KgaA 22
Novartis AG 23
Osmotica Pharmaceutical Corp. 24
Raptor Pharmaceuticals Corp. 25
SciFluor Life Sciences, LLC 26
Spasticity - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
ADX-71441 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
arbaclofen ER - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CTP-354 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dronabinol - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
incobotulinumtoxin A - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
nabiximols - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NGX-426 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
onabotulinumtoxin A - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
selurampanel - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule for Spasticity - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tezampanel - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
VSN-16R - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Spasticity - Recent Pipeline Updates 54
Spasticity - Dormant Projects 63
Spasticity - Discontinued Products 64
Spasticity - Product Development Milestones 65
Featured News & Press Releases 65
Oct 13, 2014: Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity 65
Jul 16, 2014: Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity 66
Oct 02, 2013: GW Pharmaceuticals Announces New Sativex Data at ECTRIMS 66
Aug 14, 2013: GW Pharmaceuticals Opens an Investigational New Drug Application in the United States for a Sativex Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis 68
Jul 11, 2013: Echo Pharmaceuticals Announces Phase 2 Results for Namisol, Its' Pipeline Product for Oral Administration of ?9-Tetrahydrocannabinol and Appoints The Sage Group 68
Jun 10, 2013: Concert Pharma Initiates Phase I Clinical Trial Of CTP-354 For Treatment Of Spasticity And Pain 69
May 07, 2013: GW Pharma Announces Sativex Commercialization Approval In Italy 70
Apr 10, 2013: GW Pharma's Sativex Moved To Schedule 4 Of UK Drugs Act 70
Mar 19, 2013: GW Pharma Provides Update On Pricing Negotiations For Sativex In Germany 71
Dec 10, 2012: Osmotica Pharma Initiates Phase III Studies With Arbaclofen ER Tablets 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables
Number of Products under Development for Spasticity, H2 2014 8
Number of Products under Development for Spasticity - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Spasticity - Pipeline by Addex Therapeutics Ltd, H2 2014 16
Spasticity - Pipeline by Canbex Therapeutics Ltd., H2 2014 17
Spasticity - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 18
Spasticity - Pipeline by Echo Pharmaceuticals B.V., H2 2014 19
Spasticity - Pipeline by Escape Therapeutics, Inc., H2 2014 20
Spasticity - Pipeline by GW Pharmaceuticals plc, H2 2014 21
Spasticity - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2014 22
Spasticity - Pipeline by Novartis AG, H2 2014 23
Spasticity - Pipeline by Osmotica Pharmaceutical Corp., H2 2014 24
Spasticity - Pipeline by Raptor Pharmaceuticals Corp., H2 2014 25
Spasticity - Pipeline by SciFluor Life Sciences, LLC, H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Spasticity Therapeutics - Recent Pipeline Updates, H2 2014 54
Spasticity - Dormant Projects, H2 2014 63
Spasticity - Discontinued Products, H2 2014 64